

## Committee Print

[SHOWING THE TEXT OF H.R. 1550, AS FAVORABLY FORWARDED BY THE  
ENERGY AND COMMERCE SUBCOMMITTEE ON HEALTH ON JULY 15, 2021]

117TH CONGRESS  
1ST SESSION

# H. R. 1550

To amend the Public Health Service Act to provide for a public awareness  
campaign with respect to human papillomavirus, and for other purposes.

---

IN THE HOUSE OF REPRESENTATIVES

MARCH 3, 2021

Ms. CASTOR of Florida (for herself and Ms. SCHRIER) introduced the  
following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act to provide for  
a public awareness campaign with respect to human  
papillomavirus, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Promoting Resources  
5 to Expand Vaccination, Education, and New Treatments  
6 for HPV Cancers Act of 2021” or the “PREVENT HPV  
7 Cancers Act of 2021”.

1 **SEC. 2. PREVENTING HPV AND HPV-ASSOCIATED CANCERS;**  
2 **REAUTHORIZING JOHANNA’S LAW.**

3 Section 317P of the Public Health Service Act (42  
4 U.S.C. 247b–17) is amended—

5 (1) in subsection (c)(1)—

6 (A) in subparagraph (B), by striking “cer-  
7 vical” each time it appears;

8 (B) in subparagraph (C), by striking  
9 “and” at the end;

10 (C) in subparagraph (D) by striking  
11 “other” and all that follows through “cancer.”  
12 and inserting “recommended diagnostics for  
13 early intervention for, and prevention of, HPV-  
14 associated cancers; and”; and

15 (D) by adding at the end the following:

16 “(E) the importance of recommended vac-  
17 cines for prevention of HPV and HPV-associ-  
18 ated cancers, including for males;”; and

19 (2) by amending subsection (d) to read as fol-  
20 lows:

21 “(d) JOHANNA’S LAW.—

22 “(1) NATIONAL PUBLIC AWARENESS CAM-  
23 PAIGN.—

24 “(A) IN GENERAL.—The Secretary shall  
25 carry out a national campaign to increase the  
26 awareness and knowledge of health care pro-

1           viders and individuals with respect to  
2           gynecologic cancers, HPV, and HPV-associated  
3           cancers, and the importance of HPV vaccines in  
4           preventing HPV and HPV-associated cancers.

5           “(B) WRITTEN MATERIALS.—Activities  
6           under the national campaign under subpara-  
7           graph (A) shall include—

8                   “(i) maintaining a supply of written  
9                   materials that provide information to the  
10                  public on gynecologic cancers, HPV, and  
11                  HPV-associated cancers; and

12                  “(ii) distributing the materials to  
13                  members of the public upon request.

14           “(C) PUBLIC SERVICE ANNOUNCE-  
15           MENTS.—Activities under the national cam-  
16           paign under subparagraph (A) shall, in accord-  
17           ance with applicable law and regulations, in-  
18           clude publishing materials in digital or print  
19           form, public engagement, and developing and  
20           placing public service announcements intended  
21           to encourage individuals to discuss with their  
22           physicians—

23                   “(i) their risk of gynecologic cancers  
24                   and HPV-associated cancers; and

1                   “(ii) the importance of HPV vaccines  
2                   in preventing HPV and HPV-associated  
3                   cancers.

4                   “(D) TARGETED POPULATIONS.—Activities  
5                   under the national campaign under subpara-  
6                   graph (A) shall include culturally and linguis-  
7                   tically competent public service announcements  
8                   and other forms of communication and public  
9                   engagement under subparagraph (C) targeted  
10                  to—

11                   “(i) specific higher-risk populations of  
12                   individuals based on race, ethnicity, level of  
13                   acculturation, and family history, including  
14                   African-American and Ashkenazi Jewish  
15                   individuals;

16                   “(ii) communities with high rates of  
17                   unvaccinated individuals, including males;

18                   “(iii) rural communities;

19                   “(iv) populations affected by increas-  
20                   ing rates of oropharynx cancers; and

21                   “(v) such other communities as the  
22                   Secretary determines appropriate.

23                   “(2) CONSULTATION.—In carrying out the na-  
24                   tional campaign under this section, the Secretary  
25                   shall consult with—

1 “(A) health care providers;

2 “(B) nonprofit organizations (including  
3 gynecologic cancer organizations and organiza-  
4 tions that represent communities and individ-  
5 uals most affected by HPV-associated cancers  
6 and low vaccination rates);

7 “(C) State and local public health depart-  
8 ments; and

9 “(D) elementary and secondary education  
10 organizations and institutions of higher edu-  
11 cation.

12 “(3) DEMONSTRATION PROJECTS REGARDING  
13 OUTREACH AND EDUCATION STRATEGIES.—

14 “(A) IN GENERAL.—

15 “(i) PROGRAM.—The Secretary may  
16 carry out a program to award grants or  
17 contracts to public or nonprofit private en-  
18 tities for the purpose of carrying out dem-  
19 onstration projects to test, compare, and  
20 evaluate different evidence-based outreach  
21 and education strategies to increase the  
22 awareness and knowledge of women, their  
23 families, physicians, nurses, and other key  
24 health professionals with respect to  
25 gynecologic cancers, including with respect

1 to early warning signs, risk factors, pre-  
2 vention, screening, and treatment options.

3 “(ii) SCIENCE-BASED RESOURCES.—

4 In making awards under clause (i), the  
5 Secretary shall encourage awardees to use  
6 science-based resources such as the Inside  
7 Knowledge About Gynecologic Cancer edu-  
8 cation campaign of the Centers for Disease  
9 Control and Prevention.

10 “(B) PREFERENCES IN AWARDING GRANTS  
11 OR CONTRACTS.—In making awards under sub-  
12 paragraph (A), the Secretary shall give pref-  
13 erence to—

14 “(i) applicants with demonstrated ex-  
15 pertise in gynecologic cancer education or  
16 treatment or in working with groups of  
17 women who are at increased risk of  
18 gynecologic cancers; and

19 “(ii) applicants that, in the dem-  
20 onstration project funded by the grant or  
21 contract, will establish linkages between  
22 physicians, nurses, other key health profes-  
23 sionals, health profession students, hos-  
24 pitals, payers, and State health depart-  
25 ments.

1           “(C) APPLICATION.—To seek a grant or  
2 contract under subparagraph (A), an entity  
3 shall submit an application to the Secretary in  
4 such form, in such manner, and containing such  
5 agreements, assurances, and information as the  
6 Secretary determines to be necessary to carry  
7 out this paragraph.

8           “(D) CERTAIN REQUIREMENTS.—In mak-  
9 ing awards under subparagraph (A), the Sec-  
10 retary shall—

11                   “(i) make awards, as practicable, to  
12 not fewer than five applicants; and

13                   “(ii) ensure that information provided  
14 through demonstration projects under this  
15 paragraph is consistent with the best avail-  
16 able medical information.

17           “(E) REPORT TO CONGRESS.—Not later  
18 than 24 months after the date of the enactment  
19 of the PREVENT HPV Cancers Act of 2021,  
20 and annually thereafter, the Secretary shall  
21 submit to the Committee on Energy and Com-  
22 merce of the House of Representatives and the  
23 Committee on Health, Education, Labor, and  
24 Pensions of the Senate a report that—

1                   “(i) summarizes the activities of dem-  
2                   onstration projects under subparagraph  
3                   (A);

4                   “(ii) evaluates the extent to which the  
5                   projects were effective in increasing aware-  
6                   ness and knowledge of risk factors and  
7                   early warning signs in the populations to  
8                   which the projects were directed; and

9                   “(iii) identifies barriers to early detec-  
10                  tion and appropriate treatment of such  
11                  cancers.

12                  “(4) AUTHORIZATION OF APPROPRIATIONS.—  
13                  For the purpose of carrying out this subsection,  
14                  there is authorized to be appropriated \$25,000,000  
15                  for the period of fiscal years 2022 through 2026.”.